Cover Image
市場調查報告書

藥物輸送技術的全球市場:2016-2026的預測

Drug Delivery Technologies Market Forecast 2016-2026

出版商 Visiongain Ltd 商品編碼 233148
出版日期 內容資訊 英文 214 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
藥物輸送技術的全球市場:2016-2026的預測 Drug Delivery Technologies Market Forecast 2016-2026
出版日期: 2016年07月20日 內容資訊: 英文 214 Pages
簡介

全球藥物輸送技術市場上的收益預計2020年達到2,591億美元。

本報告以全球藥物輸送技術技術市場為焦點,提供主要的藥物輸送技術,次級市場及主要國家市場的趨勢及預測,主要企業簡介,SWOT分析及專家的見解彙整。

第1章 報告概要

  • 全球藥物輸送技術市場概要
  • 全球藥物輸送技術市場區分
  • 推薦本報告的理由
  • 本報告的提供方法
  • 這個分析報告闡明的主要疑問
  • 主要讀者
  • 調查手法
  • 常見問題 (FAQ)
  • 相關報告
  • 關於Visiongain

第2章 藥物輸送技術:簡介

  • 藥物輸送技術 (DDT) :為了改善傳統治療藥的策略
  • 全球藥物輸送技術市場:給藥手段
  • 美國的法規
  • 生技藥品
  • 市場定義

第3章 藥物輸送技術:全球市場

  • 全球藥物輸送技術市場
  • 全球藥物輸送技術市場預測
  • 藥物輸送技術:促進要素、阻礙要素
  • 生技藥品:藥物輸送技術的促進成長要素
    • 全球生技藥品市場預測
    • 生技藥品的主要級
    • 單株抗體:生技藥品的最大部門
    • 胰島素注射液:主要的治療蛋白質市場區隔
    • 肝炎治療用的干擾素產品
  • 疫苗:未滿足需求的應對
    • 全球疫苗市場預測

第4章 藥物輸送技術的次級市場

  • 全球藥物輸送技術市場:各次級市場
  • 各市場區隔的市場佔有率的變化預測
  • 口服藥輸送技術
    • 口服藥輸送技術市場預測
    • 趨勢、發展
    • 口服藥輸送技術:促進要素、抑制因素
  • 吸入藥輸送技術
  • 注射/植入輸送技術
  • 經皮藥輸送技術
  • 眼藥輸送技術
  • 經鼻/口腔藥輸送技術

第5章 藥物輸送技術:主要國家市場

  • 全球藥物輸送技術市場:各地區的預測
    • 市場佔有率的變化預測
  • 美國的藥物輸送技術市場
    • 市場預測
    • Eli Lilly 成立藥物輸送中心
  • 歐盟5國的藥物輸送技術市場
    • 市場預測
    • 各國的年複合成長率
    • 各國的市場佔有率變化預測
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
  • 日本的藥物輸送技術市場
    • 市場預測
    • 先驅審查指定制度加速創新的藥物開發
  • 中國的藥物輸送技術市場
    • 市場預測
  • 印度的藥物輸送技術市場
    • 市場預測
  • 巴西的藥物輸送技術市場
    • 市場預測
  • 俄羅斯的藥物輸送技術市場
    • 市場預測
  • 韓國的藥物輸送技術市場
    • 市場預測
  • 墨西哥的藥物輸送技術市場
    • 市場預測
  • 其他藥物輸送技術市場

第6章 藥物輸送技術市場上的主要企業

  • Alkermes
  • 3M
  • Skyepharma
  • Becton Dickinson and Company (BD)
  • Antares Pharma
  • pSivida
  • Applied Pharma Research (APR)
  • Ethypharm
  • Glycologic
  • Nanopass Technologies

第7章 藥物輸送技術市場定性分析

  • 藥物輸送技術市場SWOT分析
  • 優勢
  • 弱點
  • 機會
  • 威脅

第8章 專家的見解

第9章 整體概述

  • 全球藥物輸送技術市場
    • 目前主要藥物輸送技術區分
    • 關注的藥物輸送技術企業
    • 主要的地區/國家市場
  • 全球藥物輸送技術市場預測
  • 藥物輸送技術市場未來
    • 經皮藥、注射藥輸送技術有高成長姿態
    • 生物藥物、生技仿製藥促進市場成長

第10章 用語

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0129

Title:
Drug Delivery Technologies Market Forecast 2016-2026
Analysis of Oral, Inhalable, Injectable/Implantable, Transdermal, Ocular and Nasal/Buccal Drug Delivery Technologies; Forecasts for Biologics, Vaccines and Major National Markets and Assessment of Leading Drug Delivery Companies including 3M, BD and Alkermes.

What can be expected from the Drug Delivery Technologies Market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects.

Our 214-page report provides 137 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across all the major regional and national drug delivery technologies market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2016-2026 and other analyses show you commercial prospects

Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT analysis) and commercial developments.

See revenue forecasts for the leading regional and national markets

How will leading national and regional markets perform to 2026? Our study forecasts revenues in national markets, including:

  • US
  • EU5 (Germany, France, UK, Spain and Italy)
  • Japan
  • China
  • India
  • Brazil
  • Russia
  • South Korea
  • Mexico
  • Rest of the World

Leading companies and potential for market growth

Visiongain forecasts overall revenue for the Drug Delivery Technologies Market will reach $259.1bn in 2020. We predict high revenue growth over the forecast period driven by big pharma seeking diversification of their top-selling products and a growing demand for more patient-friendly treatments in healthcare.

Our work analyses the key companies in the market. See visiongain's analysis of ten leading companies, including:

  • Alkermes
  • 3M
  • Skyepharma
  • Becton Dickinson and Company (BD)
  • Antares Pharma
  • pSivida
  • Applied Pharma Research (APR)
  • Ethypharm
  • Glycologic
  • NanoPass Technologies

A company profile gives you the following information where available:

  • Discussion of a company's activities and outlook including regional and national revenue shares
  • Historic revenue, analysis and discussion of company performance
  • Analysis of major products/services currently available on the market
  • Acquisitions and strategic partnerships

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect the drug delivery technologies industry?

Our new report discusses issues and events affecting the drug delivery technologies market. You will find discussions, including qualitative analyses:

  • Highly fragmented and competitive market with significant variations in different geographic regions
  • Changing political and regulatory landscape changing the prospects of future products and reimbursement opportunities
  • Future opportunities for drug delivery technologies

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Drug Delivery Technologies Market Forecast 2016-2026: Analysis of Oral, Inhalable, Injectable/Implantable, Transdermal, Ocular and Nasal/Buccal Drug Delivery Technologies; Forecasts for Biologics, Vaccines and Major National Markets and Assessment of Leading Drug Delivery Companies including 3M, BD and Alkermes report helps you:

In summary, our 214-page report gives you the following knowledge:

  • Revenue forecasts to 2026 for the Drug Delivery Technologies market - discover the industry's prospects, finding promising places for investments and revenues
  • Revenue forecasts to 2026 for three major regional markets - US, EU5 and Rest of the World
  • Revenue forecasts to 2026 for the leading national markets - US, Germany, France, UK, Spain, Italy, Japan, China, India, Brazil, Russia, South Korea, Mexico and Rest of the World
  • Assessment of leading companies - analysis of services, business operations, revenue (where available) and mergers & acquisitions
  • Discussion of what stimulates and restrains companies and the market
  • Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the drug delivery technologies market and leading companies. You will find data, trends and predictions. Please order our report now.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Drug Delivery Technology Market Overview
  • 1.2. Global Drug Delivery Technologies Market Segmentation
  • 1.3. Why You Should Read This Report
  • 1.4. How This Report Delivers
  • 1.5. Key Questions Answered by This Analytical Report
  • 1.6. Who Is This Report For?
  • 1.7. Methodology
  • 1.8. Frequently Asked Questions (FAQ)
  • 1.9. Associated Visiongain Reports
  • 1.10. About Visiongain

2. Drug Delivery Technology: An Introduction

  • 2.1. Drug Delivery Technologies: Strategies to Improve Existing Drugs
  • 2.2. The Global Drug Delivery Technology Market: Methods of Administration
    • 2.2.1. The Biopharmaceutics Classification System and Using Better Tools to Model Drug Absorption
    • 2.2.2. Sustained/Controlled Release Systems
    • 2.2.3. Oral Drug Delivery: Swallowing Drugs to Reach a Target
    • 2.2.4. Pulmonary Delivery: Delivered by Inhalation
    • 2.2.5. Injection as a Route of Drug Delivery
    • 2.2.6. Transdermal Delivery: More Patient-Friendly
    • 2.2.7. Various Transmucosal Delivery Routes for Delivery
    • 2.2.8. Ocular Delivery: Overcoming Unique Barriers
  • 2.3. Regulation in the US
    • 2.3.1. Regulation of Combination Products
    • 2.3.2. FDA Guidelines for Injectors
  • 2.4. Biopharmaceuticals
    • 2.4.1. An Introduction to the Biological Drugs Market
    • 2.4.2. Biologics: A Rising Drugs Market
    • 2.4.3. Biologics with Associated Drug Delivery Technologies
    • 2.4.4. Pegylated Interferons
    • 2.4.5. Stiff Competition in Insulin Market Stimulating Investment in Drug Delivery Technologies
    • 2.4.6. The Main Challenges Facing Biological Drug Delivery
  • 2.5. Market Definition

3. Drug Delivery Technologies: Global Market, 2016-2026

  • 3.1. The Global Drug Delivery Technology Market in 2015
  • 3.2. The Global Drug Delivery Technology Market Forecast 2016-2026
  • 3.3. Drug Delivery Technology: Drivers and Restraints 2016-2026
  • 3.4. Biologics: A Driver for Growth in Drug Delivery Technologies
    • 3.4.1. The Global Biological Drugs Market Forecast
    • 3.4.2. Leading Classes of Biological Drugs
    • 3.4.3. Monoclonal Antibodies: Largest Sector in Biologics
    • 3.4.4. Human insulin: Leading the Therapeutic Protein Segment
    • 3.4.5. Interferon Products for the Treatment of Hepatitis
  • 3.5. Vaccines: Meeting the Unmet Needs
    • 3.5.1. The Global Vaccines Market Forecast

4. Drug Delivery Technologies: Submarkets 2016-2026

  • 4.1. The Global Drug Delivery Technology Market by Submarkets
  • 4.2. How Will Segmental Market Shares Change to 2026?
  • 4.3. Oral Drug Delivery Technology
    • 4.3.1. Oral Drug Delivery Technology Market Forecast 2016-2026
    • 4.3.2. Trends and Developments
      • 4.3.2.1. Delivering APIs to the Colon
      • 4.3.2.2. Google Investing in Robotic Pill
    • 4.3.3. Oral Drug Delivery Technologies: Drivers and Restraints 2016-2026
  • 4.4. Inhalable Drug Delivery Technology
    • 4.4.1. Inhalable Drug Delivery Technology Market Forecast 2016-2026
    • 4.4.2. Trends and Developments
      • 4.4.2.1. Inhalable Liposomal Antibiotics to Penetrate Biofilms
      • 4.4.2.2. Condensation Aerosol Generated by Heat
      • 4.4.2.3. Is Inhaled Insulin Marketable?
    • 4.4.3. Inhalable Drug Delivery Technologies: Drivers and Restraints 2016-2026
  • 4.5. Injectable/Implantable Delivery Technology
    • 4.5.1. Injectable/Implantable Delivery Technology Market Forecast 2016-2026
    • 4.5.2. Trends and Developments
      • 4.5.2.1. Ultrasound Activated Targeted Drug Delivery
      • 4.5.2.2. Intradermal Vaccine Delivery
      • 4.5.2.3. First Flu Vaccine Jet Injector Approved in the US
    • 4.5.3. Injectable/Implantable Delivery Technologies: Drivers and Restraints 2016-2026
  • 4.6. Transdermal Drug Delivery Technology
    • 4.6.1. Transdermal Drug Delivery Technology Market Forecast 2016-2026
    • 4.6.2. Trends and Developments
      • 4.6.2.1. Iontophoretic Transdermal Patch for Migraine Approved in the US
      • 4.6.2.2. Microneedle Patch for Vaccine Delivery
      • 4.6.2.3. Ultrasonic Waveforms to Enlarge Skin Pores
  • 4.7. Ocular Drug Delivery Technology
    • 4.7.1. Ocular Drug Delivery Technology Market Forecast 2016-2026
    • 4.7.2. Trends and Developments
      • 4.7.2.1. Non-Surgical Microinjection to Retina and Choroid to be used for Gene Therapy
  • 4.8. Nasal/Buccal Drug Delivery Technology
    • 4.8.1. Nasal/Buccal Drug Delivery Technology Market Forecast 2015-2026
    • 4.8.2. Trends and Developments
      • 4.8.2.1. Nasal Spray with Live Attenuated Influenza Vaccine
      • 4.8.2.2. Mucosal Vaccine Delivered through the Nose or Mouth
      • 4.8.2.3. Buccal Insulin Spray in Clinical Trials

5. Drug Delivery Technologies: Leading National Markets, 2016-2026

  • 5.1. Global Drug Delivery Technology Market: Regional Forecast 2016-2026
    • 5.1.1. How Will Regional Market Shares Change to 2026?
  • 5.2. US Drug Delivery Technology Market 2016-2026
    • 5.2.1. US Drug Delivery Technology Market Forecast 2016-2026
    • 5.2.2. Eli Lilly to Establish Drug Delivery Centre
  • 5.3. EU5. Drug Delivery Technology Market 2016-2026
    • 5.3.1. EU5. Drug Delivery Technology Market Forecast 2016-2026
    • 5.3.2. EU5. Drug Delivery Technologies Market: CAGR (%) by Country, 2016-2026
    • 5.3.3. EU5. Markets: Changing Market Shares by Country, 2016-2026
    • 5.3.4. The German Drug Delivery Technology Market Forecast 2016-2026
    • 5.3.5. The French Drug Delivery Technology Market Forecast 2016-2026
    • 5.3.6. The UK Drug Delivery Technology Market Forecast 2016-2026
    • 5.3.7. The Spanish Drug Delivery Technology Market Forecast 2016-2026
    • 5.3.8. The Italian Drug Delivery Technology Market Forecast 2016-2026
  • 5.4. Japanese Drug Delivery Technology Market 2016-2026
    • 5.4.1. Japanese Drug Delivery Technology Market Forecast 2016-2026
    • 5.4.2. The New Sakigake Designation System May Accelerate Innovative Drug Development
  • 5.5. Chinese Drug Delivery Technology Market 2016-2026
    • 5.5.1. Chinese Drug Delivery Technology Market Forecast 2016-2026
  • 5.6. Indian Drug Delivery Technology Market 2016-2026
    • 5.6.1. Indian Drug Delivery Technology Market Forecast 2016-2026
  • 5.7. Brazilian Drug Delivery Technology Market 2016-2026
    • 5.7.1. Brazilian Drug Delivery Technology Market Forecast 2016-2026
  • 5.8. Russian Drug Delivery Technology Market 2016-2026
    • 5.8.1. Russian Drug Delivery Technology Market Forecast 2016-2026
  • 5.9. South Korean Drug Delivery Technology Market 2016-2026
    • 5.9.1. South Korean Drug Delivery Technology Market Forecast 2016-2026
  • 5.10. Mexican Drug Delivery Technology Market 2016-2026
    • 5.10.1. Mexican Drug Delivery Technology Market Forecast 2016-2026
  • 5.11. Rest of the World Drug Delivery Technology Market Forecast 2016-2026

6. Leading Companies in the Drug Delivery Technology Market, 2016-2026

  • 6.1. Alkermes: Focused on Extended and Controlled Release
    • 6.1.1. Alkermes: Drug Delivery Technology Portfolio
    • 6.1.2. Long-Acting Injectables
    • 6.1.3. Aristada vs. Abilify Maintena
    • 6.1.4. Oral Controlled Release
      • 6.1.4.1. Nanoparticle Technologies
    • 6.1.5. Other Technologies
    • 6.1.6. Alkermes: Product Portfolio
    • 6.1.7. Alkermes: Pipeline Products 2016
    • 6.1.8. Alkermes Recent Developments
      • 6.1.8.1. Merger with Elan Drug Technologies
      • 6.1.8.2. Alkermes: Future Outlook
    • 6.1.9. Manufacturing Facility in Georgia Sold to Recro Pharma
  • 6.2. 3M: 50. Years of Drug Delivery Technology Development
    • 6.2.1. 3M: Drug Delivery Technology Portfolio
      • 6.2.1.1. Oral and Topical Drug Delivery
      • 6.2.1.2. MDI for Nasal and Inhalable Drugs
      • 6.2.1.3. Transdermal patch Technology
      • 6.2.1.4. Microneedle Technology
    • 6.2.2. 3M: Market Outlook
  • 6.3. Skyepharma: Solutions for Inhalable, Oral, Topical and Injectable Drugs
    • 6.3.1. Skyepharma: Drug Delivery Technology Portfolio
      • 6.3.1.1. Inhalation Drug Delivery Technology
      • 6.3.1.2. Oral Drug Delivery Technology
      • 6.3.1.3. Injectable Drug Delivery Technology
      • 6.3.1.4. Topical Drug Delivery Technology
    • 6.3.2. Skyepharma: Pipeline Products 2016
    • 6.3.3. Skyepharma: Market Outlook
  • 6.4. Becton Dickinson and Company (BD): A History of Hypodermic Needles and Syringes
    • 6.4.1. BD: Drug Delivery Technology Portfolio
      • 6.4.1.1. Prefillable Syringe Systems
      • 6.4.1.2. Self-Injection Systems
      • 6.4.1.3. Pen Needles
      • 6.4.1.4. Safety & Shielding Systems
    • 6.4.2. BD: Future Outlook
    • 6.4.3. New Infusion Set with BD FlowSmart Technology Cleared by FDA
    • 6.4.4. BD Acquired Injection Safety Firms
  • 6.5. Antares Pharma: Leading the Needle-Free Injector Market
    • 6.5.1. Antares Pharma: Drug Delivery Product Portfolio
    • 6.5.2. Antares Pharma: Future Outlook
    • 6.5.3. Antares Pharma: Products in Development
  • 6.6. pSivida: Targeting the Back of the Eye
    • 6.6.1. pSivida: Drug Delivery Technology Portfolio
      • 6.6.1.1. Durasert Technology
      • 6.6.1.2. Tethadur Technology
    • 6.6.2. pSivida: Pipeline Products 2016
    • 6.6.3. pSidiva: Collaborations
    • 6.6.4. pSivida: Future Outlook
  • 6.7. Applied Pharma Research (APR)
    • 6.7.1. APR's Technology and Product Offerings
  • 6.8. Ethypharm
    • 6.8.1. Ethypharm's Currently Marketed Products
  • 6.9. Glycologic
    • 6.9.1. Glycologic's Drug Delivery Technologies
    • 6.9.2. Glycologic's Pipeline Developments
  • 6.10. NanoPass Technologies
    • 6.10.1. NanoPass Drug Delivery Products
      • 6.10.1.1. Anti-aging Microdermabrasion
      • 6.10.1.2. MicronJet Needle

7. Qualitative Analysis of the Drug Delivery Technology Market, 2016-2026

  • 7.1. SWOT Analysis of the Drug Delivery Technology Market
  • 7.2. Strengths
    • 7.2.1. Increasing Competition and Patent Expiry in the Biologics Market
    • 7.2.2. The Rise of Biosimilars
    • 7.2.3. Increasing Global Diabetic Population
  • 7.3. Weaknesses
    • 7.3.1. Risk-Conscious Regulatory Bodies Will Make Approval Difficult
    • 7.3.2. Companies Need to Develop a More Liberal Mindset
  • 7.4. Opportunities
    • 7.4.1. Nanotechnology: Innovations That Will Benefit Drug Delivery
    • 7.4.2. Possible New Delivery Methods for Insulin
  • 7.5. Threats
    • 7.5.1. Increasing Specificity of Drug Development Poses Challenges to Speciality Drug Delivery Companies
    • 7.5.2. Cost Effective Solutions May Not Be Available

8. Expert Opinions from Our Primary Research

  • 8.1. Mr. Patrice Lewko, Vice President - Global Marketing & Innovation, Nemera
    • 8.1.1. The Current state of the Drug Delivery Technologies Market
    • 8.1.2. Key Pointers to Entering the Drug Delivery Technologies Market
    • 8.1.3. The Key to Success for Novelia
    • 8.1.4. Regions of Interest for Nemera and Prospects for Future Growth
    • 8.1.5. Prospects for New Technologies
    • 8.1.6. Major Challenges and Opportunities
  • 8.2. Mr. Armand Amin, Manager - Systems Development, BioDuro
    • 8.2.1. BioDuro Drug Delivery Technology Solutions
    • 8.2.2. The Importance of Timing
    • 8.2.3. The Current State of the Drug Delivery Technologies Market
    • 8.2.4. Entering the Drug Delivery Technologies Market
    • 8.2.5. New Technologies to Enter the Market
    • 8.2.6. Future Challenges and Opportunities for Drug Delivery Technologies
    • 8.2.7. Opportunities for Growth

9. Conclusions

  • 9.1. The Global Drug Delivery Technologies Market in 2015
    • 9.1.1. Current Leading Drug Delivery Technology Segments
    • 9.1.2. Notable Drug Delivery Technology Companies
    • 9.1.3. Leading Regional/National Markets
  • 9.2. Global Drug Delivery Technology Market Forecast 2016-2026
  • 9.3. The Future of the Drug Delivery Technology Market
    • 9.3.1. Transdermal and Injectable Drug Delivery Technologies Set For High Growth
    • 9.3.2. Biologics and Biosimilars to Drive Market Growth

10. Glossary

Appendix

  • Visiongain's Bespoke Research Service
  • Some Associated Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Report Evaluation Form

List of Tables

  • Table 1.1: Global Drug Delivery Technologies Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Region, 2015-2026 (Redacted Data)
  • Table 2.1: The Biopharmaceutics Classification System, Classification and Description
  • Table 2.2: Top 5 Biologics by Sales ($bn), 2015
  • Table 3.1: The Global Drug Delivery Technology Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 3.2: Global Biological Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 3.3: Global Vaccines Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 4.1: The Global Drug Delivery Technology Market by Submarkets: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 4.2: Leading Drug Delivery Market Segments: CAGR (%), 2015-2020, 2020-2026 and 2015-2026
  • Table 4.3: Leading Drug Delivery Market Segments: Market Share (%), 2015
  • Table 4.4: Oral Drug Delivery Technology Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 4.5: Inhalable Drug Delivery Technology Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 4.6: Insulin Inhalers Withdrawal from the Market or Pipeline, 2016
  • Table 4.7: Injectable/Implantable Drug Delivery Technology Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 4.8: Transdermal Drug Delivery Technology Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 4.9: Ocular Drug Delivery Technology Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 4.10: Nasal/Buccal Drug Delivery Technology Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 5.1: The Global Drug Delivery Technologies Market by Country/Region: Revenue ($bn) and Market Share (%), 2015
  • Table 5.2: Global Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Country/Region, 2015-2026
  • Table 5.3: Global Drug Delivery Technology Market: Revenue ($bn) by Country/Region, 2015, 2020 and 2026
  • Table 5.4: Global Drug Delivery Technology Market: Revenue ($bn) and Market Share (%) by Country/Region, 2015
  • Table 5.5: US Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 5.6: EU5 Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 5.7: EU5 Drug Delivery Technology Market: CAGR (%) by Country, 2015-2020, 2020-2026 and 2015-2026
  • Table 5.8: EU5 Drug Delivery Technology Market: Market Size ($bn) and Market Share (%) by Country, 2015, 2020 and 2026
  • Table 5.9: German Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 5.10: French Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 5.11: UK Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 5.12: Spanish Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 5.13: Italian Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 5.14: Japanese Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 5.15: Chinese Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 5.16: Indian Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 5.17: Brazilian Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
  • Table 5.18: Russian Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 5.19: South Korean Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 5.20: Mexican Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 5.21: Rest of the World Drug Delivery Technology Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Table 6.1: Leading Companies: Areas of Interest by Type of Delivery
  • Table 6.2: Alkermes: Overview, 2016
  • Table 6.3: Alkermes: Drug Delivery Technology Portfolio and Pipeline 2016
  • Table 6.4: Products Utilising Alkermes' Drug Delivery Technology (Indication, Partner and Territory) 2016
  • Table 6.5: Alkermes: Pipeline Products (Product Candidate, Target Indication and Status), 2016
  • Table 6.6: Alkermes: Historical Revenue ($m), AGR (%) and CAGR (%), 2010-2015
  • Table 6.7: Alkermes: Historical Revenue ($m) by Business Segment, 2010-2015
  • Table 6.8: Alkermes: Manufacturing and Royalty Revenue ($m) by Product, 2014 and 2015
  • Table 6.9: Alkermes: Revenue ($m) by Main Customers 2014
  • Table 6.10: 3M: Overview, 2016
  • Table 6.11: 3M: Health Care Historical Revenue ($bn), AGR (%) and CAGR (%), 2010-2015
  • Table 6.12: Skyepharma: Overview, 2015
  • Table 6.13: Skyepharma: Inhalation Drug Formulation Technology Portfolio 2016
  • Table 6.14: Products Utilising Skyepharma's Inhalation Drug Delivery Technology (Product Name, Indication, Licensee and Description), 2015
  • Table 6.15: Skyepharma: Oral Drug Formulation Technology Portfolio (Technology, Description and Product Name) 2016
  • Table 6.16: Products Utilising Skyepharma's Oral Drug Delivery Technology (Product Name, Indication, Licensee and Description), 2016
  • Table 6.17: Skyepharma: Pipeline Products 2016 (Product Name, Formulation, Region, Indication, Partner Name and Status)
  • Table 6.18: Skyepharma: Historical Revenue ($m), AGR (%) and CAGR (%), 2010-2015
  • Table 6.19: Skyepharma: Historical Revenue ($m) by Income Stream, 2010-2015
  • Table 6.20: BD: Overview, 2016
  • Table 6.21: BD: Drug Delivery Products by Segment, 2016
  • Table 6.22: BD: Historical Revenue ($bn) by Geographic Region, 2012-2015
  • Table 6.23: BD Medical: Historical Revenue ($bn), AGR (%) and CAGR (%), 2010-2015
  • Table 6.24: Antares Pharma: Overview, 2016
  • Table 6.25: Antares Pharma: Product Portfolio (Product, Drug, Partner, Indication and Territory
  • Table 6.26: Antares Revenue from Major Customers: Revenue ($m) and Revenue Share (%), 2014 and 2015
  • Table 6.27: Antares Revenue by Region: Revenue ($m) and Revenue Share (%), 2014 and 2015
  • Table 6.28: Antares Pharma: Historical Revenue ($m), AGR (%) and CAGR (%), 2010-2015
  • Table 6.29: Antares Pharma: Products in Development 2016 (Product Name, Drug, Partner, Indication, Territory and Regulatory Status)
  • Table 6.30: pSivida: Overview, 2015
  • Table 6.31: Products Utilising Durasert Technology 2015 (Product, Indication, Status and Partner)
  • Table 6.32: pSivida: Historical Revenue ($m), AGR (%) and CAGR (%), 2010-2015
  • Table 6.33: pSivida: Historical Revenue ($m) by Income Stream, 2010-2015
  • Table 6.34: Selected Ethypharm's Pain Relieving Products, 2015
  • Table 7.1: SWOT Analysis of the Drug Delivery Technology Market, 2016-2026

List of Figures

  • Figure 3.1: The Global Drug Delivery Technology Market: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 3.2: Drug Delivery Technologies: Market Drivers and Restraints 2016-2026
  • Figure 3.3: Global Biological Drugs Market: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 3.4: Global Vaccines Market: Revenues ($bn) and AGR (%), 2015-2026
  • Figure 4.1: Leading Drug Delivery Market Segments: CAGR (%), 2015-2020
  • Figure 4.2: Leading Drug Delivery Market Segments: CAGR (%), 2020-2026
  • Figure 4.3: Leading Drug Delivery Market Segments: CAGR (%), 2015-2026
  • Figure 4.4: Market Shares (%) of Leading Drug Delivery Market Segments, 2015
  • Figure 4.5: Market Shares (%) of Leading Drug Delivery Market Segments, 2020
  • Figure 4.6: Market Shares (%) of Leading Drug Delivery Market Segments, 2026
  • Figure 4.7: Oral Drug Delivery Technology Market: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 4.8: Oral Drug Delivery Technologies: Drivers and Restraints 2016-2026
  • Figure 4.9: Inhalable Drug Delivery Technology Market: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 4.10: Inhalable Drug Delivery Technologies: Drivers and Restraints 2016-2026
  • Figure 4.11: Injectable/Implantable Drug Delivery Technology Market: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 4.12: Injectable/implantable Drug Delivery Technologies: Drivers and Restraints 2015-2026
  • Figure 4.13: Transdermal Drug Delivery Technology Market: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 4.14: Ocular Drug Delivery Technology Market: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 4.15: Nasal/Buccal Drug Delivery Technology Market: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 5.1: The Global Drug Delivery Technologies Market by Country/Region: Revenue ($bn), 2015
  • Figure 5.2: Global Drug Delivery Technology Market: Revenue ($bn) by Country/Region, 2015, 2020 and 2026
  • Figure 5.3: Global Drug Delivery Technology Market: CAGR (%) by Country/Region, 2015-2020
  • Figure 5.4: Global Drug Delivery Technology Market: CAGR (%) by Country/Region, 2020-2026
  • Figure 5.5: Global Drug Delivery Technology Market: CAGR (%) by Country/Region 2015-2026
  • Figure 5.6: Global Drug Delivery Technology Market: Market Share (%) by Country/Region, 2015
  • Figure 5.7: Global Drug Delivery Technology Market: Market Share (%) by Country/Region, 2020
  • Figure 5.8: Global Drug Delivery Technology Market: Market Share (%) by Country/Region, 2026
  • Figure 5.9: US Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 5.10: EU5 Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 5.11: EU5 Drug Delivery Technology Market: CAGR (%) by Country, 2015-2020
  • Figure 5.12: EU5 Drug Delivery Technology Market: by Country, 2020-2026
  • Figure 5.13: EU5 Drug Delivery Technology Market: CAGR (%) by Country, 2015-2026
  • Figure 5.14: EU5 Drug Delivery Technology Market: Market Share (%) by Country, 2015
  • Figure 5.15: EU5 Drug Delivery Technology Market: Market Share (%) by Country, 2020
  • Figure 5.16: EU5 Drug Delivery Technology Market: Market Share (%) by Country, 2026
  • Figure 5.17: German Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 5.18: French Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 5.19: UK Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 5.20: Spanish Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 5.21: Italian Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 5.22: Japanese Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 5.23: Chinese Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 5.24: Indian Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 5.25: Brazilian Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 5.26: Russian Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 5.27: South Korean Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 5.28: Mexican Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 5.29: Rest of the World Drug Delivery Technology Market Forecast: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 6.1: Alkermes: Historical Revenue ($m) and AGR (%), 2010-2015
  • Figure 6.2: Alkermes Historical Revenue ($m): Manufacturing and Royalty Turnover, and Net Product Sales, 2010-2015
  • Figure 6.3: Alkermes: Manufacturing and Royalty Revenue ($m) by Product, 2014 and 2015
  • Figure 6.4: Alkermes: Revenue Share (%) by Main Customers 2014
  • Figure 6.5: Alkermes: Revenue Share (%) by Main Customers 2015
  • Figure 6.6: 3M: Health Care Historical Revenue ($bn) and AGR (%), 2010-2015
  • Figure 6.7: Skyepharma: Historical Revenue ($m) and AGR (%), 2010-2015
  • Figure 6.8: Skyepharma: Historical Revenue ($m) by Income Stream, 2010-2015
  • Figure 6.9: BD: Historical Revenue ($bn) by Geographic Region, 2012-2015
  • Figure 6.10: BD Medical: Historical Revenue ($bn) and AGR (%), 2010-2015
  • Figure 6.11: Antares Revenue from Major Customers: Revenue Share (%), 2014
  • Figure 6.12: Antares Revenue from Major Customers: Revenue Share (%), 2015
  • Figure 6.13: Antares Revenue by Region: Revenue Share (%), 2014
  • Figure 6.14: Antares Revenue by Region: Revenue Share (%), 2015
  • Figure 6.15: Antares Pharma: Historical Revenue ($m) and AGR (%), 2010-2015
  • Figure 6.16: pSivida: Historical Revenue ($m) and AGR (%), 2010-2015
  • Figure 6.17: pSivida: Historical Revenue ($m) by Income Stream, 2010-2015

Companies Listed

  • 3M
  • Acorda
  • Actavis
  • Adamis
  • Aleza Pharmaceuticals
  • Alkermes
  • Almirall
  • Alza
  • Antares Pharma
  • Applied Pharma Research
  • Aradigm
  • Astellas
  • AstraZeneca
  • Bayer HealthCare Pharmaceuticals
  • BD
  • Biogen
  • BioGeneration Ventures
  • Bioject Medical Technologies
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • CareFusion Corporation
  • Cephalon
  • Changchun BCHT
  • Chiesi
  • Chrono Therapeutics
  • Cilag
  • Cima Labs
  • Clearside
  • Cosmo Pharmaceuticals
  • CRISI Medical Systems
  • CTCBIO
  • Daiichi
  • Elan Drug Technologies
  • Elcam Medical
  • Eli Lilly
  • Ethypharm
  • Ferrer
  • Ferring
  • Flamel
  • Genentech
  • GlaxoSmithKline
  • Glycologic
  • Google
  • GSK
  • Haselmeir
  • Horizon Pharma
  • ImmusanT
  • Innovent Biologics
  • Insmed
  • Invion
  • iScience Interventional Corporation
  • J&J
  • Janssen
  • JCR Pharmaceuticals
  • Kyorin
  • MannKind
  • Meda Pharmaceuticals
  • Medac
  • Medimetrics
  • MedImmune
  • MedSciences Capital
  • Merck Serono
  • Mucosis
  • Mundipharma
  • Nanopass Technologies
  • Nektar Therapeutics
  • Nexvax2
  • NHTherapeutics
  • Novartis
  • Novo Nordisk
  • NuPathe
  • NV NOM
  • Oramed
  • OwenMumford
  • Pacira Pharmaceuticals
  • Pari Pharma
  • Permatec
  • Pfizer
  • PharmaJet
  • Presspart
  • ProStrakan
  • pSivida
  • Pulmagen
  • Ranbaxy
  • Rani Therapeutics
  • Recro Pharma
  • Regeneron Pharmaceuticals
  • Roche
  • Sandoz
  • Sanofi-Aventis
  • Santen
  • Shionogi
  • SHL Group
  • Shreya Life Sciences
  • Skyepharma
  • Smoofi
  • Spark Therapeutics
  • STADA Arzneimittel
  • Takeda
  • Teva
  • UU Holdings
  • Vetter Pharma
  • West Pharmaceuticals
  • Ypsomed

Organisations Mentioned in the Report

  • Emory University School of Medicine
  • Georgia Institute of Technology
  • Hospital for Special Surgery
  • University of Oxford
Back to Top